Kisqali and Mean cell haemoglobin increased - a phase IV clinical study of FDA data

Summary:

Mean cell haemoglobin increased is reported as a side effect among people who take Kisqali (ribociclib succinate), especially for people who are female, 60+ old, have been taking the drug for 2 - 5 years also take Zoledronic Acid, and have Breast cancer.

The phase IV clinical study analyzes which people have Mean cell haemoglobin increased when taking Kisqali. It is created by eHealthMe based on reports of 25,037 people who have side effects when taking Kisqali from the FDA, and is updated regularly.

What is Kisqali?

Kisqali has active ingredients of ribociclib succinate. eHealthMe is studying from 25,050 Kisqali users. Check the latest studies of Kisqali.

What is Mean cell haemoglobin increased?

Mean cell haemoglobin increased (more than normal haemoglobin per red blood cell in a sample of blood) is found to be associated with 308 drugs and 366 conditions by eHealthMe. Check the latest studies of Mean cell haemoglobin increased.

On Aug, 08, 2026

25,037 people reported to have side effects when taking Kisqali.
Among them, 54 people (0.22%) have Mean cell haemoglobin increased.

Could Kisqali cause Mean cell haemoglobin increased?

Among these 54 people:

How long have people been on Kisqali when they have Mean cell haemoglobin increased? *

What is the gender of people who have Mean cell haemoglobin increased when taking Kisqali? *

female: 100 %
male: 0.0 %

What is the age of people who have Mean cell haemoglobin increased when taking Kisqali? *

What are other drugs people take besides Kisqali? *

What are other side effects people have besides Mean cell haemoglobin increased? *

Red Blood Cell Count Decreased: 54 people, 100.00%
White Blood Cell Count Decreased: 45 people, 83.33%
Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 40 people, 74.07%
Red Cell Distribution Width Increased: 39 people, 72.22%
Mean Cell Volume Increased (more than normal average red blood cell volume): 38 people, 70.37%
Haematocrit Decreased: 36 people, 66.67%
Macrocytosis (enlargement of red blood cells with near-constant haemoglobin concentration): 35 people, 64.81%
Anisocytosis (patient's red blood cells are of unequal size): 33 people, 61.11%
Haemoglobin Decreased: 27 people, 50.00%
Lymphocyte Count Decreased: 25 people, 46.30%

What are the existing conditions these people have? *

Breast Cancer: 41 people, 75.93%
Breast Cancer Metastatic: 14 people, 25.93%
Bone Disorder: 6 people, 11.11%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 5 people, 9.26%
Neuralgia (pain in one or more nerves): 5 people, 9.26%
High Blood Pressure: 5 people, 9.26%
Neoplasm Malignant (cancer tumour): 4 people, 7.41%
Metastases To Breast (cancer spreads to brain): 2 people, 3.70%
Synovial Cyst (cyst of joint filled with synovial fluid): 1 person, 1.85%
Metastasis (spreadable cancer to other organ from origin): 1 person, 1.85%

* Approximation only. Some reports may have incomplete information.

Do you take Kisqali and have Mean cell haemoglobin increased?

- Check whether Mean cell haemoglobin increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Kisqali:

Kisqali (25,050 reports)

Browse all side effects of Kisqali:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Mean cell haemoglobin increased:

Mean cell haemoglobin increased (308 drugs)

Browse all the conditions that are associated with Mean cell haemoglobin increased:

Mean cell haemoglobin increased (366 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ribociclib succinate (the active ingredients of Kisqali) and Kisqali (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.